What Elpida Therapeutics does

Elpida Therapeutics is a 501(c)(3) nonprofit biotechnology organization operating as a Social Purpose Corporation, founded in April 2019 by Terry Pirovolakis after his youngest son Michael was diagnosed with SPG50, an ultra-rare hereditary disease causing progressive paralysis. Headquartered in Encino, California with 1–10 employees, Elpida develops AAV9 (adeno-associated virus serotype 9) gene therapies for children affected by ultra-rare neurodegenerative conditions, with a current pipeline spanning SPG50 (lead asset MELPIDA / Michael's Hope, in US pivotal Phase III as of April 2026), CLN7 Batten disease, Charcot Marie Tooth Disease Type 4J (CMT4J), and an RBM28-related disease program developed with the Let's Cure Lucas foundation. The organization pursues a '5x programs' strategy aiming to take five gene therapies from proof-of-concept to BLA approval within 2–3 years, dosing 8–12 children per program, and anticipates receiving two Priority Review Vouchers that could fund development of 16 additional programs. Access to investigational therapies is delivered through clinical trials and a case-by-case Expanded Access Program; therapies are not commercially priced.

Elpida does not operate a commercial revenue model. It is funded through donations from a global base of 'tens of thousands of donors,' crowdfunding (PayPal donate button on website), research and clinical grants — including a disclosed $3,930,964 award from the California Institute for Regenerative Medicine in May 2025 — and partnership support. The May 2026 LifeArc partnership provides clinical, translational, and regulatory expertise alongside financial support for three programs (SPG50, CLN7 Batten disease, CMT4J) with UK and Europe focus and an ambition for FDA approval on SPG50 by early 2028. Additional ecosystem ties include the NIH Bespoke Gene Therapy Consortium (BGTC), PaVe-GT, UT Southwestern, SickKids Hospital, and a network of clinical principal investigators at leading academic medical centers. As a matter of policy, Elpida does not allow payment of indirect costs or overhead to institutions, channeling resources directly into therapy development and prioritizing affordability for patients.

The organization also operates a mission-driven nonprofit biotech consultancy (serving foundations, families, and small biotechs with regulatory planning, CMC, clinical operations, fundraising readiness, and program management) and an RBM28 grant program. It has secured Orphan Drug Designation and Rare Pediatric Disease Designation on its programs and pursues marketing channels centered on organic social media (LinkedIn, Facebook, Twitter, Instagram), podcast appearances, press releases, and earned media rather than paid acquisition.

Name

Elpida Therapeutics

Legal name

Elpida Therapeutics

Website

https://elpidatx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Elpida Therapeutics is a 501(c)(3) nonprofit biotech developing AAV9 gene therapies for children with ultra-rare neurodegenerative diseases (SPG50, CLN7 Batten disease, CMT4J, RBM28), funded by donations, grants, and partnerships, with lead asset MELPIDA now in US pivotal Phase III.

Ownership category

akta.pro rank

Product category

Rare Disease Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

AAV Vector Gene Therapy Developers (HLAAACAA), Neurology/CNS Gene Therapies (HLAAACAH), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Gene therapy development
• Rare disease therapeutics
• AAV9 gene therapy
• Pediatric neurodegenerative treatment
• Ultra-rare disease research

Headquarters

HQ city

Encino

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Donations and Crowdfunding: Nonprofit model supported by tens of thousands of donors from around the world who contributed to fund the MELPIDA gene therapy development
2. Grants and Foundation Funding: Research and clinical grant applications for advancing therapies, including partnership with Let's Cure Lucas for RBM28-related disease research
3. Partnership Support: LifeArc provides clinical, translational, and regulatory expertise alongside financial support for gene therapy program development

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Elpida Therapeutics develops AAV9-based gene therapies for ultra-rare pediatric neurodegenerative diseases, with MELPIDA (Michael's Hope) as the lead candidate targeting SPG50. The organization runs a 5x Programs Initiative to advance five gene therapy programs from proof-of-concept to BLA approval, while also offering a biotech consultancy service for foundations and small biotech companies.

Product overview

Elpida Therapeutics is a 501(c)(3) non-profit biotech organization (operating as a Social Purpose Corporation) developing gene therapies for ultra-rare diseases in children. The company's core offerings include MELPIDA (Michael's Hope), an AAv9 gene therapy for SPG50, alongside four additional pipeline programs targeting CLN7 Batten disease and CMT4J. Elpida operates a 5x programs initiative aiming to take five programs from proof-of-concept to BLA approval, each dosing 8-12 children. Supporting services include a biotech consultancy helping foundations and small biotech companies with regulatory planning, CMC, clinical operations, and program management; an Expanded Access Program for investigational therapies; and a grant program for RBM28-related disease research in partnership with Let's Cure Lucas.

Differentiator

Problem solved

Functional benefit

Products and services

• MELPIDA (Michael's Hope) AAV9 Gene Therapy AAV9 gene therapy for SPG50 (spastic paraplegia 50), a rare hereditary disease causing progressive paralysis in children. Developed for patients with no available treatment options.
• SPG50 Gene Therapy Program Gene therapy program for SPG50 (spastic paraplegia 50), a rare hereditary disease. Currently in US pivotal Phase III trial with first patients recruited in April 2026.
• CLN7 Batten Disease Gene Therapy Program Gene therapy program targeting CLN7 Batten disease, an ultra-rare neurodegenerative condition in children.
• CMT4J Gene Therapy Program Gene therapy program for Charcot Marie Tooth Disease Type 4J, an ultra-rare neurodegenerative condition, including a Natural History Study.
• Biotech Consultancy Services Consultancy service supporting foundations, families, and small biotech companies with regulatory planning, CMC, clinical operations, fundraising readiness, and cross-functional program management for advancing programs from proof-of-concept through clinical development.
• Expanded Access Program Program providing access to investigational gene therapies for patients with serious or immediately life-threatening conditions who cannot qualify for or access clinical studies and have no satisfactory therapeutic alternatives. Access determined on a case-by-case basis considering drug supply, funding, clinical team capabilities, and patient condition severity.
• RBM28 Disease Grant Program Research and clinical grant program focused on advancing therapies, natural history research, and clinical outcomes for children affected by RBM28-related disease, in partnership with Let's Cure Lucas foundation.

Quantifiable outcome

• First patients recruited to US pivotal Phase III trial for SPG50 with ambition for FDA approval by early 2028
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and major.

• LifeArccoreStrategic or Co-development Partner · 27 May 2026LifeArc, a UK medical research organization, has partnered with Elpida Therapeutics to support development of three gene therapy programs targeting ultra-rare neurodegenerative conditions in children (SPG50, CLN7 Batten disease, and CMT4J). LifeArc provides clinical, translational, and regulatory expertise alongside financial support, with focus on UK and Europe, aiming to create a blueprint for developing rare disease therapies. The partnership aims to achieve FDA approval for SPG50 by early 2028.
• Let's Cure LucascoreStrategic or Co-development PartnerPartnership with Let's Cure Lucas foundation to seek research and clinical grant applications focused on advancing therapies for RBM28-related disease. Funding priorities include gene therapy development, translational and preclinical research, biomarker development, and supportive care initiatives.
• NIH (Foundation and Research Institutions)majorStrategic or Co-development PartnerNIH Partnership Announcement including collaboration with BGTC (Bespoke Gene Therapy Consortium) and PaVe-GT (Platform Vector Engine for Gene Therapy). Partners on regulatory playbooks and templates for Rare Pediatric Disease Designation and Orphan Drug Designation applications.
• UT SouthwesternmajorStrategic or Co-development PartnerPartnership with UT Southwestern for gene therapy clinical trials, as referenced in their newsroom articles.
• SickKids HospitalmajorStrategic or Co-development PartnerSickKids Hospital collaboration including podcast appearances discussing Elpida's origins and rare disease research.
• Clinical PI TeammajorOthersClinical Principal Investigators including Steven Gray, Berge Minassian, James Dowling, Susan Iannaccone, Michael Shy, John Day, Benjamin Greenberg, Saima Kayani, Lorenzo D'Antiga, and others at leading academic medical centers supporting clinical trial execution.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Pfizer (Gene Therapy Unit): Large biopharma with active gene therapy operations and rare disease programs, including beqvez for hemophilia B. Comparable in AAV modality and rare disease focus, but at global pharma scale.
• BioMarin Pharmaceutical: Established rare disease biopharma with approved gene therapy (Roctavian) and active rare pediatric programs. Comparable in rare disease mission and gene therapy modality, but with far greater resources and commercial reach.
• Spark Therapeutics: Gene therapy company (acquired by Roche) with approved AAV product (Luxturna) and active rare disease pipeline. Comparable in AAV gene therapy modality and rare disease focus, now operating as part of a large incumbent.
• BridgeBio Pharma: Rare disease biopharma with multiple programs across genetic and CNS conditions. Comparable in rare monogenic disease focus, though operates with a broader small-molecule and gene therapy pipeline.
• Ultragenyx Pharmaceutical: Commercial-stage rare disease company with multiple late-stage gene therapy programs. Comparable to Elpida in rare pediatric disease focus but operates at much larger scale with broader modality mix.

Direct peers

• Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based therapies for rare monogenic diseases of the CNS. Directly comparable to Elpida given shared AAV platform approach to ultra-rare neurological conditions.
• uniQure: Clinical-stage gene therapy company developing AAV-based treatments for rare and serious diseases, with a CNS-focused pipeline. Directly comparable in modality (AAV) and indication strategy (rare neurological).
• Asklepios BioPharmaceutical: AAV gene therapy company (acquired by Bayer) developing treatments for rare neurological and neuromuscular diseases. Directly comparable in AAV platform and CNS rare disease focus, with greater resources post-acquisition.
• Regenxbio: AAV gene therapy platform company with multiple programs in rare diseases, including CNS indications. Comparable to Elpida in AAV technology and rare disease focus, though at substantially larger scale and broader pipeline.

Regional players

• PTC Therapeutics: Commercial-stage rare disease company with gene therapy programs and active rare pediatric neurology focus (e.g., Duchenne programs). Comparable in ultra-rare pediatric disease strategy and gene therapy modality, though with broader commercial portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/elpidatx
• Facebookfacebook.com/elpidatx
• LinkedInlinkedin.com/company/elpidatx
• Instagraminstagram.com/elpidatx

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elpida Therapeutics